Table 3 Internal validation of the estrogen receptor (ER)-specific risk prediction models (ModelFR+ and ModelFR-) by fivefold cross-validation, overall and by age, in the women from the European Prospective Investigation into Cancer and Nutrition (EPIC) study
From: Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts
ModelER+ | ModelER- | Omnibus model | |
|---|---|---|---|
C-statistic (95% CI) | |||
Before eliminating country effect | 0.68 (0.65–0.70) | 0.68 (0.64–0.72) | 0.68 (0.66–0.70) |
After eliminating country effect | |||
Overall | 0.64 (0.61–0.67) | 0.59 (0.54–0.64) | 0.63 (0.60–0.65) |
By menopausal status | |||
Premenopausal | 0.64 (0.59–0.68) | 0.58 (0.51–0.66) | 0.62 (0.59–0.66) |
Postmenopausal | 0.62 (0.59–0.66) | 0.60 (0.52–0.67) | 0.62 (0.59–0.65) |
By ER status | |||
ER+ | – | – | 0.64 (0.62–0.67) |
ER− | – | – | 0.59 (0.53–0.64) |
Ratio of observed–expected (95% CI) | |||
Overall | 1.10 (1.05–1.14) | 0.96 (0.88–1.05) | 1.07 (1.03–1.11) |
By menopausal status | |||
Premenopausal | 1.13 (1.06–1.20) | 0.97 (0.85–1.10) | 1.09 (1.02–1.15) |
Postmenopausal | 1.07 (1.02–1.13) | 0.96 (0.84–1.08) | 1.06 (1.00–1.11) |